Literature DB >> 21783272

Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression.

Isabel Y Pappworth1, Christine Hayes, Jason Dimmick, B Paul Morgan, V Michael Holers, Kevin J Marchbank.   

Abstract

We have previously demonstrated that mice expressing human complement receptor type 2 (CR2/CD21) during the CD43(+)/CD25(-) late pro-B cell stage of B cell development have marked changes in their subsequent B cell ontogeny. Here, we show that the humoral immune response to the T cell dependent antigen, sheep red blood cells (SRBCs) can be moderately enhanced with the addition of human CR1 (driven by the lambda promoter/enhancer transgene) to endogenous mCR1/CR2 expression on the B cell surface but that hCR1 expression alone (on the mouse CR1/2 deficient background) has no effect on the humoral immune response or general B cell development. Furthermore, expression of hCR1 had no recuperative effect on the markedly altered B cell phenotype noted with premature expression of hCR2 (either in the presence or absence of endogenous mCR1/2). We conclude that hCR1 alone cannot replace the role of CR2 in mice and that the effects of premature hCR2 expression during BCR development are not significantly altered by the addition of hCR1 at that developmental stage or beyond; thus hCR2 signaling in the mouse remains dominant over subsequent input from either hCR1 or endogenous receptors.
Copyright © 2011 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21783272      PMCID: PMC5638010          DOI: 10.1016/j.imbio.2011.06.001

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  59 in total

Review 1.  The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function.

Authors:  V M Holers; T Kinoshita; H Molina
Journal:  Immunol Today       Date:  1992-06

Review 2.  The who, how and where of antigen presentation to B cells.

Authors:  Facundo D Batista; Naomi E Harwood
Journal:  Nat Rev Immunol       Date:  2009-01       Impact factor: 53.106

3.  Complement receptor 1 expression on mouse erythrocytes mediates clearance of Streptococcus pneumoniae by immune adherence.

Authors:  Jie Li; Jennifer P Wang; Ionita Ghiran; Anna Cerny; Alexander J Szalai; David E Briles; Robert W Finberg
Journal:  Infect Immun       Date:  2010-05-03       Impact factor: 3.441

4.  Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response.

Authors:  Y Fang; C Xu; Y X Fu; V M Holers; H Molina
Journal:  J Immunol       Date:  1998-06-01       Impact factor: 5.422

5.  Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen.

Authors:  J M Ahearn; M B Fischer; D Croix; S Goerg; M Ma; J Xia; X Zhou; R G Howard; T L Rothstein; M C Carroll
Journal:  Immunity       Date:  1996-03       Impact factor: 31.745

6.  B cells from mice prematurely expressing human complement receptor type 2 are unresponsive to T-dependent antigens.

Authors:  Louise Birrell; Liudmila Kulik; B Paul Morgan; V Michael Holers; Kevin J Marchbank
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

7.  Expression of human complement receptor 2 (CR2, CD21) in Cr2-/- mice restores humoral immune function.

Authors:  K J Marchbank; C C Watson; D F Ritsema; V M Holers
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

8.  Expression of human complement receptor type 2 (CD21) in mice during early B cell development results in a reduction in mature B cells and hypogammaglobulinemia.

Authors:  Kevin J Marchbank; Liudmila Kulik; Matthew G Gipson; B Paul Morgan; V Michael Holers
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

9.  Complement receptors 1 and 2 influence the immune environment in a B cell receptor-independent manner.

Authors:  Amanda C Jacobson; Janis J Weis; John H Weis
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

10.  First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigen-heteropolymer ETI-104.

Authors:  C Iking-Konert; S Stocks; F Weinsberg; R Engelbrecht; E Bleck; A Perniok; R Fischer-Betz; S Pincus; L Nardone; M Schneider
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

View more
  6 in total

1.  Generation of a novel Cr2 gene allele by homologous recombination that abrogates production of Cr2 but is sufficient for expression of Cr1.

Authors:  Luke R Donius; Christopher M Orlando; Janis J Weis; John H Weis
Journal:  Immunobiology       Date:  2013-08-21       Impact factor: 3.144

Review 2.  Complement and the Regulation of T Cell Responses.

Authors:  Erin E West; Martin Kolev; Claudia Kemper
Journal:  Annu Rev Immunol       Date:  2018-04-26       Impact factor: 28.527

3.  Optimal germinal center B cell activation and T-dependent antibody responses require expression of the mouse complement receptor Cr1.

Authors:  Luke R Donius; Jennifer M Handy; Janis J Weis; John H Weis
Journal:  J Immunol       Date:  2013-06-03       Impact factor: 5.422

4.  Mesenchymal stem cells infected with Mycoplasma arginini secrete complement C3 to regulate immunoglobulin production in B lymphocytes.

Authors:  D-S Lee; T G Yi; H-J Lee; S-N Kim; S Park; M-S Jeon; S U Song
Journal:  Cell Death Dis       Date:  2014-04-24       Impact factor: 8.469

5.  A novel mouse model expressing human forms for complement receptors CR1 and CR2.

Authors:  Harriet M Jackson; Kate E Foley; Rita O'Rourke; Timothy M Stearns; Dina Fathalla; B Paul Morgan; Gareth R Howell
Journal:  BMC Genet       Date:  2020-09-09       Impact factor: 2.797

6.  A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice.

Authors:  Yong-Gang He; Isabel Y Pappworth; Andreas Rossbach; Joshua Paulin; Tarirai Mavimba; Christine Hayes; Liudmila Kulik; V Michael Holers; Andrew M Knight; Kevin J Marchbank
Journal:  Immunobiology       Date:  2017-10-04       Impact factor: 3.144

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.